Thus we hypothesised that C1498-luc that express homogenous level of H-2Kb could be more susceptible to PLK1122DC_TriVax with PD-L1 blockade therapeutic regime, and that superior therapeutic effects against clonally heterogeneous C1498 leukaemia could be achieved with multi-antigen-specific CD8 T-cells targeting multi-epitopes bound to both MHC-I allele, H-2Db and H-2Kb to attenuate in vivo-escaping of tumour cell clones. The gene discussed is CD274; the disease is neoplasm.